Systems pharmacology strategies for drug discovery and combination with applications to cardiovascular diseases.

ETHNOPHARMACOLOGICAL RELEVANCE Multi-target therapeutics is a promising paradigm for drug discovery which is expected to produce greater levels of efficacy with fewer adverse effects and toxicity than monotherapies. Medical herbs featuring multi-components and multi-targets may serve as valuable resources for network-based multi-target drug discovery. MATERIALS AND METHODS In this study, we report an integrated systems pharmacology platform for drug discovery and combination, with a typical example applied to herbal medicines in the treatment of cardiovascular diseases. RESULTS First, a disease-specific drug-target network was constructed and examined at systems level to capture the key disease-relevant biology for discovery of multi-targeted agents. Second, considering an integration of disease complexity and multilevel connectivity, a comprehensive database of literature-reported associations, chemicals and pharmacology for herbal medicines was designed. Third, a large-scale systematic analysis combining pharmacokinetics, chemogenomics, pharmacology and systems biology data through computational methods was performed and validated experimentally, which results in a superior output of information for systematic drug design strategies for complex diseases. CONCLUSIONS This strategy integrating different types of technologies is expected to help create new opportunities for drug discovery and combination.

[1]  David J. Reiss,et al.  Niche adaptation by expansion and reprogramming of general transcription factors , 2011, Molecular systems biology.

[2]  Xing-Ming Zhao,et al.  Exploring drug combinations in genetic interaction network , 2012, BMC Bioinformatics.

[3]  T. Cheng.  Cardiovascular effects of Danshen. , 2007, International journal of cardiology.

[4]  S. Buchanan,et al.  Refolding of G-Protein-Coupled Receptors , 2006 .

[5]  J. Loscalzo,et al.  The Emerging Paradigm of Network Medicine in the Study of Human Disease , 2012, Circulation research.

[6]  Sean Ekins,et al.  Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. , 2005, Trends in pharmacological sciences.

[7]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[8]  M. Drab,et al.  Loss of Caveolae, Vascular Dysfunction, and Pulmonary Defects in Caveolin-1 Gene-Disrupted Mice , 2001, Science.

[9]  Peng Jiang,et al.  Molecular networks for the study of TCM Pharmacology , 2010, Briefings Bioinform..

[10]  D. Noble,et al.  Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.

[11]  L. Claesson‐Welsh,et al.  FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. , 2001, Trends in pharmacological sciences.

[12]  Yonghua Wang,et al.  Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication , 2012, Integrative biology : quantitative biosciences from nano to macro.

[13]  S. Morris.  Arginine metabolism in vascular biology and disease , 2005, Vascular medicine.

[14]  R. Touyz.  Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology. , 2005, Antioxidants & redox signaling.

[15]  Yang Chu,et al.  The effect of Compound Danshen Dripping Pills, a Chinese herb medicine, on the pharmacokinetics and pharmacodynamics of warfarin in rats. , 2011, Journal of ethnopharmacology.

[16]  Miklos Feher,et al.  Property Distributions: Differences Between Drugs, Natural Products, and Molecules from Combinatorial Chemistry. , 2003 .

[17]  Chuan Li.  Absorption, disposition, and pharmacokinetics of herbal medicines: what and how? , 2012, Current drug metabolism.

[18]  Mike Tyers,et al.  Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole , 2011, Molecular systems biology.

[19]  Bao-yan Liu,et al.  Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine. , 2012, Journal of ethnopharmacology.

[20]  D. Mangelsdorf,et al.  Liver X receptor signaling pathways in cardiovascular disease. , 2003, Molecular endocrinology.

[21]  Xingming Zhao,et al.  A Network Biology Approach to Understand Combination of Drugs , 2010 .

[22]  Zhao-quan Huang,et al.  Vasorelaxant Effects of Icariin on Isolated Canine Coronary Artery , 2007, Journal of cardiovascular pharmacology.

[23]  Haiyun Ling,et al.  Corydalis yanhusuo rhizoma extract reduces infarct size and improves heart function during myocardial ischemia/reperfusion by inhibiting apoptosis in rats , 2006, Phytotherapy research : PTR.

[24]  F. W. Tan,et al.  Structure-activity relationship of miltirone, an active central benzodiazepine receptor ligand isolated from Salvia miltiorrhiza Bunge (Danshen). , 1991, Journal of medicinal chemistry.

[25]  B Xie,et al.  Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. , 2009, Drug discovery today.

[26]  C. Harris,et al.  Chemogenomics: structuring the drug discovery process to gene families. , 2006, Drug discovery today.

[27]  De-Xin Kong,et al.  Where is the hope for drug discovery? Let history tell the future. , 2009, Drug discovery today.

[28]  Jean-Guy Berrin,et al.  Deglycosylation by small intestinal epithelial cell β-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans , 2003, European journal of nutrition.

[29]  Hua Yu,et al.  A Systematic Prediction of Multiple Drug-Target Interactions from Chemical, Genomic, and Pharmacological Data , 2012, PloS one.

[30]  Bo Zhang,et al.  Network target for screening synergistic drug combinations with application to traditional Chinese medicine , 2011, BMC Systems Biology.

[31]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[32]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[33]  R. Rothman,et al.  Serotonergic drugs and valvular heart disease , 2009, Expert opinion on drug safety.

[34]  Tingjun Hou,et al.  Recent development and application of virtual screening in drug discovery: an overview. , 2004, Current pharmaceutical design.

[35]  M. Won,et al.  Syringaresinol causes vasorelaxation by elevating nitric oxide production through the phosphorylation and dimerization of endothelial nitric oxide synthase , 2011, Experimental & Molecular Medicine.

[36]  B. Kobilka,et al.  β-Adrenergic Receptor Subtype-Specific Signaling in Cardiac Myocytes from β1 and β2 Adrenoceptor Knockout Mice , 2001 .

[37]  Xue Xu,et al.  A System-Level Investigation into the Mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for Cardiovascular Disease Treatment , 2012, PloS one.

[38]  Xue Xu,et al.  A Systems Biology Approach to Uncovering Pharmacological Synergy in Herbal Medicines with Applications to Cardiovascular Disease , 2012, Evidence-based complementary and alternative medicine : eCAM.

[39]  Y. Tsao,et al.  PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells. , 2007, Cardiovascular research.

[40]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[41]  A Yagi,et al.  Possible Aktive Components of Tan-Shen (Salvia miltiorrhiza) for Protection of the Myocardium Against Ischemia-Induced Derangements , 1989, Planta medica.

[42]  Wei Niu,et al.  Intestinal absorption and presystemic elimination of various chemical constituents present in GBE50 extract, a standardized extract of Ginkgo biloba leaves. , 2012, Current drug metabolism.

[43]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Hua Yu,et al.  A Novel Chemometric Method for the Prediction of Human Oral Bioavailability , 2012, International journal of molecular sciences.

[45]  S. Schuster,et al.  Metabolic network structure determines key aspects of functionality and regulation , 2002, Nature.

[46]  Adriano Lazzarin,et al.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial , 2009, The Lancet.

[47]  Wei Niu,et al.  INTESTINAL ABSORPTION AND PRESYSTEMIC ELIMINATION OF VARIOUS CHEMICAL CONSTITUENTS PRESENTIN GBE50 EXTRACT, A STANDARDIZED EXTRACT OF GINKGO BILOBA LEAVES , 2012 .

[48]  M. Danhof,et al.  Commentary: "A systems view on the future of medicine: inspiration from Chinese medicine?". , 2009, Journal of ethnopharmacology.

[49]  Yi Sun,et al.  Towards a bioinformatics analysis of anti-Alzheimer's herbal medicines from a target network perspective , 2013, Briefings Bioinform..

[50]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[51]  S. Lee,et al.  Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery , 2011, Molecular systems biology.

[52]  M. Mocanu,et al.  Postconditioning: A Form of “Modified Reperfusion” Protects the Myocardium by Activating the Phosphatidylinositol 3-Kinase–Akt Pathway , 2004, Circulation research.

[53]  R. Bauer,et al.  Traditional Chinese medicine research in the post-genomic era: good practice, priorities, challenges and opportunities. , 2012, Journal of ethnopharmacology.

[54]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[55]  Michael Costanzo,et al.  Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.

[56]  R. Iyengar,et al.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.

[57]  C. Hohl,et al.  The role of arachidonic acid in rat heart cell metabolism. , 1987, Biochimica et biophysica acta.

[58]  Jian Wang,et al.  High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections , 2007, Proceedings of the National Academy of Sciences.

[59]  G. Semenza,et al.  HIF-1 and human disease: one highly involved factor. , 2000, Genes & development.

[60]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[61]  M. Spinella.  The importance of pharmacological synergy in psychoactive herbal medicines. , 2002, Alternative medicine review : a journal of clinical therapeutic.

[62]  Taixiang Wu,et al.  Danshen (Chinese medicinal herb) preparations for acute myocardial infarction. , 2008, The Cochrane database of systematic reviews.

[63]  Chuan Li.  Editorial [Hot Topic: Absorption, Disposition, and Pharmacokinetics of Herbal Medicines: What and How? (Guest Editor: Chuan Li)] , 2012 .

[64]  Y. Pang,et al.  In Silico Drug Discovery: Solving the “Target‐rich and Lead‐poor” Imbalance Using the Genome‐to‐drug‐lead Paradigm , 2007, Clinical pharmacology and therapeutics.

[65]  Jordi Mestres,et al.  A chemogenomic approach to drug discovery: focus on cardiovascular diseases. , 2009, Drug discovery today.

[66]  Gisbert Schneider,et al.  Properties and Architecture of Drugs and Natural Products Revisited , 2007 .

[67]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[68]  E. Ruppin,et al.  Predicting selective drug targets in cancer through metabolic networks , 2011, Molecular systems biology.

[69]  Ravi Iyengar,et al.  Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic , 2011 .

[70]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[71]  F. Cheung.  TCM: Made in China , 2011, Nature.

[72]  Robert J. Lefkowitz,et al.  Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases , 2012 .

[73]  I. Shiojima,et al.  Role of Akt Signaling in Vascular Homeostasis and Angiogenesis , 2002, Circulation research.

[74]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[75]  M. Galsky,et al.  Docetaxel-based combination therapy for castration-resistant prostate cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  Haiyun Wang,et al.  Pathway analysis of microRNAs in mouse heart development , 2010, Int. J. Bioinform. Res. Appl..